BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol. 2010;90:183-185. [PMID: 20169304 DOI: 10.2340/00015555-0777] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Succaria F, Bhawan J. Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective. J Dermatol 2017;44:243-50. [PMID: 28256759 DOI: 10.1111/1346-8138.13762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239. [PMID: 27493788 DOI: 10.1136/rmdopen-2015-000239] [Cited by in Crossref: 81] [Cited by in F6Publishing: 48] [Article Influence: 16.2] [Reference Citation Analysis]
3 Skalkou A, Manoli SM, Sachinidis A, Ntouros V, Petidis K, Pagkopoulou E, Vakirlis E, Pyrpasopoulou A, Dimitroulas T. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int 2018;38:161-7. [PMID: 29075910 DOI: 10.1007/s00296-017-3861-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ursini F, Naty S, Russo E, Grembiale RD. Abatacept in psoriatic arthritis: Case report and short review. J Pharmacol Pharmacother 2013;4:S29-32. [PMID: 24347977 DOI: 10.4103/0976-500X.120943] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
6 Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders. Front Pharmacol 2019;10:282. [PMID: 30971924 DOI: 10.3389/fphar.2019.00282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
7 Vasconcellos JB, Pereira DD, Vargas TJ, Levy RA, Pinheiro GD, Cursi ÍB. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol 2016;91:137-9. [PMID: 28300922 DOI: 10.1590/abd1806-4841.20164456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
8 Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1:74-78. [PMID: 24303470 DOI: 10.12998/wjcc.v1.i2.74] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
9 Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal 2014;2014:179180. [PMID: 24600322 DOI: 10.1155/2014/179180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
10 Fiorillo L, Wang C, Hemmati I. Rituximab induced psoriasis in an infant. Pediatr Dermatol 2014;31:e149-51. [PMID: 25424224 DOI: 10.1111/pde.12437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR. SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment. Curr Rheumatol Rep. 2016;18:35. [PMID: 27108452 DOI: 10.1007/s11926-016-0583-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 30] [Article Influence: 18.3] [Reference Citation Analysis]
12 Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl) 2016;6:131-44. [PMID: 29387600 DOI: 10.2147/PTT.S98954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
13 Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014;10:612-27. [DOI: 10.1038/nrrheum.2014.123] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
14 Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017;177:72-83. [PMID: 27864925 DOI: 10.1111/bjd.15193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
15 Tiwari SM, Wood BA, Skender-Kalnenas T, Cook N. A case of abatacept associated neutrophilic dermatosis and a review of the literature. Australas J Dermatol 2014;55:214-7. [PMID: 25117161 DOI: 10.1111/ajd.12185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
16 Patwardhan A, Spencer CH. Biologics in refractory idiopathic inflammatory myositis (IIM): What experience in juvenile vs adult myositis tells us about the use of biologics in pediatric IIM. Mod Rheumatol 2021;31:933-48. [PMID: 33499694 DOI: 10.1080/14397595.2021.1881027] [Reference Citation Analysis]
17 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sehgal R, Stratman EJ, Cutlan JE. Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience. Clin Med Res 2018;16:41-6. [PMID: 29610119 DOI: 10.3121/cmr.2017.1364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Brunasso AM, Massone C. Plantar pustulosis during rituximab therapy for rheumatoid arthritis. J Am Acad Dermatol 2012;67:e148-50. [PMID: 22980273 DOI: 10.1016/j.jaad.2011.12.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
20 Banse C, Sobocinski V, Savoye G, Avenel G, Vittecoq O. Occurrence of Sweet syndrome under anti-TNF. Clin Rheumatol 2015;34:1993-4. [DOI: 10.1007/s10067-015-3054-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Brunasso AMG, Sola S, Massone C. Recalcitrant psoriatic onycho-pachydermo-periostitis successfully treated with guselkumab. Clin Exp Dermatol 2021;46:789-91. [PMID: 33619743 DOI: 10.1111/ced.14459] [Reference Citation Analysis]
22 Selva-nayagam P, Fischer G, Hamann I, Sobel J, James C. Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum. Curr Infect Dis Rep 2015;17. [DOI: 10.1007/s11908-015-0478-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
23 Foti C, Tucci M, Stingeni L, Hansel K, Lospalluti L, Frisario R, Giuffrida R, Romita P. Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma. Dermatol Ther 2021;34:e14653. [PMID: 33301205 DOI: 10.1111/dth.14653] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]